Key positives include a validated antibody discovery platform, a focused and differentiated immunology pipeline, and royalty income from partnered products that partially de-risks the story compared with some development-only peers. The company still maintains adequate liquidity, has low capital expenditure needs, and has shown the ability to access capital markets and debt financing when required. Its planned separation into a royalty-focused entity and a development company may provide clearer strategic focus and potentially unlock value in each part of the business.

The main concerns are the persistent, large operating and net losses, deeply negative cash flows, and a clear trend toward higher leverage and shrinking equity. Revenue is volatile and not yet stable enough to support the current cost base. Clinical and regulatory risk is substantial, as the company’s value is concentrated in a small number of programs and in its royalty streams from a few partnered assets. The growing reliance on debt and the ongoing dispute with GSK further increase financial and legal uncertainty.

The forward picture is highly dependent on execution: clinical results for rosnilimab and ANB033, progress of earlier-stage assets, resolution of the GSK royalty litigation, and the successful completion and operation of the planned corporate split. If key programs succeed and royalty streams grow, the company could transition from a cash-burning developer to a more balanced model with meaningful recurring income. If setbacks persist and cash burn continues at current levels, the rising leverage and eroding equity base could become more pressing issues. Overall, the outlook is opportunity-rich but carries high scientific, operational, and financial risk, typical of a late-clinical-stage biotech pursuing ambitious innovation.